University of Louisville homepage
All experts
All experts

Ju-Hsien Chao

Asst Professor Term

School of Medicine

Orcid identifier0000-0002-0417-8936
  • Asst Professor Term
    School of Medicine

SPONSORED PROJECTS

Hematological malignancy

Bone marrow transplant

Cellular therapy

SPONSORED PROJECTS

  • Showing page 1 out of 2
Showing page 1, sponsored projects 1 to 25 of 35
GRANT
A Phase 1b\/2 Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19\/CD20 Bispecific CAR-T Cell Therapy in Adult Participants with B-cell Non-Hodgkin Lymphoma
Janssen Research and Development_JRAD8 Dec 2026 - 31 Dec 2026
MORELEARN MORE
GRANT
A Randomized Phase 3 Trial of Continuous vs Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)
Alliance for Clinical Trials in Onc_ACTO11 Feb 2026 - 16 Apr 2036
MORELEARN MORE
GRANT
AWD-00000434 | MM1YA-A04: Phase II Study of Cytarabine + Daunorubicin (7+3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7+3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Treatment Trial
Southwest Oncology Group_SWOG (SPN-000283)7 Jan 2026 - 31 Dec 2036
MORELEARN MORE
GRANT
AWD-00000390 | A042302: Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Alliance Foundation Trials LLC_AFT6 Jan 2026 - 31 Dec 2036
MORELEARN MORE
GRANT
AWD-00000525 | LYL314-102: A Phase 3 Randomized Controlled Trial Of Rondecabtagene Autoleucel, An Autologous, Dual-Targeting Cd19\/Cd20 Car T-Cell Product Candidate Versus Investigator\u2019s Choice Of Cd19 Car T-Cell Therapy In Patients With Relapsed Or Refractory Large B-Cell Lymphoma In The Second-Line Setting (PiNACLE-H2H)
IQVIA BioTech LLC_IQVB (SPN-002471)1 Jan 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
AWD-00000233 | MM1YA-CTG01: A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia
Southwest Oncology Group_SWOG9 Feb 2025 - 9 Jan 2030
MORELEARN MORE
GRANT
AWD-00000222 | MM1MDS-A01: A Randomized Phase II Trial of Enasidenib-Based Therapies versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A Myelomatch Sub-Study
Southwest Oncology Group_SWOG6 Jan 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
A Phase 1b Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Janssen Research and Development_JRAD1 Jan 2025 - 31 Dec 2026
MORELEARN MORE
GRANT
A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
BeiGene Ltd_BGLTD1 Jan 2025
MORELEARN MORE
GRANT
A RANDOMIZED PHASE II TRIAL OF ASTX727 AND VENETOCLAX COMPARED WITH ASTX727, VENETOCLAX, AND ENASIDENIB FOR NEWLY DIAGNOSED OLDER ADULTS WITH IDH2 MUTANT ACUTE MYELOID LEUKEMIA: A MYELOMATCH SUBSTUDY
Southwest Oncology Group_SWOG1 Jan 2025
MORELEARN MORE
GRANT
AML3001: A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
Janssen Research and Development_JRAD1 Jan 2025
MORELEARN MORE
GRANT
AWD-00000196 | A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects with Moderate to Severe Treatment-Refractory Crohn's Disease
Alimentiv Inc_ALI1 Jan 2025 - 31 Dec 2030
MORELEARN MORE
GRANT
AWD-00000245 | SNDX-5613-0708: A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
PPD Clinical Research_PCR1 Jan 2025
MORELEARN MORE
GRANT
250141|MYELOMATCH - Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Oregon Health and Science Universit_OHSU9 Dec 2024
MORELEARN MORE
GRANT
MMY1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH
Southwest Oncology Group_SWOG1 Oct 2024 - 30 Sep 2034
MORELEARN MORE
GRANT
241122|68284528MMY4006 - Intermediate-Size Population Expanded Access Program (EAP) for clita-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma
Janssen Research and Development_JRAD10 Sep 2024
MORELEARN MORE
GRANT
240695|M20-621 - A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
Syneos Health_SH11 Jan 2024
MORELEARN MORE
GRANT
240041|IOV-MEL-301 - A Phase 3, MC, R, OL, PG, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab...
PPD Clinical Research_PCR1 Jan 2024
MORELEARN MORE
GRANT
240992|ALLO-501A-202 - A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-Cell Lymphoma (Alpha3)
PSI CRO AG1 Jan 2024
MORELEARN MORE
GRANT
250290|S2114 - A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIb Follicular Lymphoma
Oregon Health and Science Universit_OHSU1 Jan 2024
MORELEARN MORE
GRANT
240373|MPCT-012L - A Phase 1/2 Multi-Center Study Evaluating the Safety And Efficacy Of Impt-314, A Cd19/20 Bispecific Chimeric Antigen Receptor (Car) T Cell Therapy In Participants With Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Medpace Inc_MPI5 Sep 2023
MORELEARN MORE
GRANT
230671|MK-1026 - A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
Merck and Company Inc_MERCKCO8 Jul 2023
MORELEARN MORE
GRANT
240315|AHOD2131 - A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Alliance for Clinical Trials in Onc_ACTO10 Feb 2023
MORELEARN MORE
GRANT
240198|OBX115 -A Ph 1/2, OL St to Investigate the Sfty and Efficacy of Membrane Bound IL-15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants w Unresectable or Metastatic Melanoma Resistant to Checkpoint Inhibitors After BRAF-MEK
Syneos Health_SH8 Jan 2023
MORELEARN MORE
GRANT
230665|ALLO-647 Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion with Fludarabine, Cyclophosphamide, and ALLO-647, VS. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Pharmaceutical Resrch Associates Inc_PRA1 Jan 2023
MORELEARN MORE